Search Results - "Bacon, James A."

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling by Posada, Maria M, Bacon, James A, Schneck, Karen B, Tirona, Rommel G, Kim, Richard B, Higgins, J William, Pak, Y Anne, Hall, Stephen D, Hillgren, Kathleen M

    Published in Drug metabolism and disposition (01-03-2015)
    “…Pemetrexed, an anionic anticancer drug with a narrow therapeutic index, is eliminated mainly by active renal tubular secretion. The in vitro to in vivo…”
    Get full text
    Journal Article
  2. 2

    Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib by Posada, Maria M., Cannady, Ellen A., Payne, Christopher D., Zhang, Xin, Bacon, James A., Pak, Y. Anne, Higgins, J. William, Shahri, Nazila, Hall, Stephen D., Hillgren, Kathleen M.

    Published in Clinical and translational science (01-11-2017)
    “…Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, undergoes active renal tubular secretion. Baricitinib was not predicted to inhibit hepatic and…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier by RONG ZHAO, RAUB, Thomas J, SAWADA, Geri A, KASPER, Steven C, BACON, James A, BRIDGES, Arlene S, POLLACK, Gary M

    Published in Drug metabolism and disposition (01-06-2009)
    “…Expression of breast cancer resistance protein (Bcrp) at the blood-brain barrier (BBB) has been revealed recently. To investigate comprehensively the potential…”
    Get full text
    Journal Article
  5. 5

    Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon by Ulrich, Roger G, Bacon, James A, Brass, Eric P, Cramer, Clay T, Petrella, Diane K, Sun, Elena L

    Published in Chemico-biological interactions (16-05-2001)
    “…Preclinical drug safety evaluation studies, typically conducted in two or more animal species, reveal and define dose-dependent toxicities and undesirable…”
    Get full text
    Journal Article
  6. 6

    Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite by Ulrich, Roger G., Bacon, James A., Cramer, Clay T., Petrella, Diane K., Sun, Elena L., Meglasson, Martin D., Holmuhamedov, Ekhson

    Published in Toxicology (Amsterdam) (02-11-1998)
    “…The quinoxalinone anxiolytic, panadiplon, was dropped from clinical development due to unexpected hepatic toxicity in human volunteers. Subsequent experimental…”
    Get full text
    Journal Article
  7. 7

    Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development by Ulrich, Roger G., Bacon, James A., Cramer, Clay T., Peng, Geoffrey W., Petrella, Diane K., Stryd, Ronald P., Sun, Elena L.

    Published in Toxicology Letters (01-12-1995)
    “…Drugs can fail at any phase during discovery, preclinical or clinical development due to unacceptable levels of toxicity, and liver is commonly the principle…”
    Get full text
    Journal Article Conference Proceeding
  8. 8

    Potentiation of hypoxic injury in cultured rabbit hepatocytes by the quinoxalinone anxiolytic, panadiplon by Bacon, James A., Cramer, Clay T., Petrella, Diane K., Sun, Elena L., Ulrich, Roger G.

    Published in Toxicology (Amsterdam) (15-04-1996)
    “…The quinoxalinone anxiolytic, panadiplon, produces hepatic metabolic inhibition (mitochondrial impairment), microvesicular steatosis and centrilobular necrosis…”
    Get full text
    Journal Article
  9. 9

    Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic by Ulrich, Roger G., Bacon, James A., Branstetter, Daniel G., Cramer, Clay T., Funk, G.Michael, Hunt, Charles E., Petrella, Diane K., Sun, Elena L.

    Published in Toxicology (Amsterdam) (12-04-1995)
    “…The non-benzodiazepine anxiolytic, panadiplon, was discontinued from clinical development due to evidence of hepatic toxicity in human volunteers that was not…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14